Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$80.34
−$0.28 · -0.35%
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Previous close
$80.34
−$0.28 · -0.35%
Regular session · ET · Market data may be delayed.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Day range
Current $80.34
52-week range
Current $80.34
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
53
Fair Value
Sentiment
38
Bearish
Risk
80
High Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Day range
Current $80.34
52-week range
Current $80.34
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 147.17M USD | 125.6M USD | 93.11M USD | 55.55M USD | 14.61M USD |
| Cost of goods sold | 209.75M USD | 203.62M USD | 188.72M USD | 172M USD | 114.62M USD |
| Gross profit | −62.57M USD | −78.02M USD | −95.61M USD | −116.45M USD | −100M USD |
| Research and development | 195.79M USD | 322.38M USD | 338.75M USD | 329.58M USD | 460.21M USD |
| Selling, general, and administrative | 275.8M USD | 367.82M USD | 362.56M USD | 296.44M USD | 234.06M USD |
| Operating expenses | 471.59M USD | 2.11B USD | 1.42B USD | 5.33B USD | 1.17B USD |
| Interest income | 28.65M USD | 26.73M USD | 7.95M USD | 1.74M USD | 332K USD |
| Depreciation and amortization | 156.34M USD | 158.06M USD | 158.7M USD | 154.76M USD | 58.45M USD |
| Operating income | −534.16M USD | −2.19B USD | −1.52B USD | −5.44B USD | −1.27B USD |
| Net income | −408.35M USD | −2.03B USD | −1.47B USD | −5.4B USD | −1.25B USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$62.75
21.89% downsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI122.24M1.06%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI84.59M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM84.47M0.11%79.88B USD0.19%$296.01+0.28%
iShares Russell 2000 Value ETFIWN30.76M0.22%14.47B USD0.24%$224.62+0.40%
Vanguard Extended Market ETFVXF25.71M0.03%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB23.51M0.22%10.72B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO15.89M0.09%17.4B USD0.06%$119.62+0.25%
Schwab U.S. Small-Cap ETFSCHA12.7M0.06%22.56B USD0.03%$34.55+1.01%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
